Marker Therapeutics, Inc.
No SEC Form 4 filings for $MRKR in the last 30 days.
See all $MRKR insider activity →Marker Therapeutics, Inc. (MRKR) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant to Advance MT-601 in Pancreatic Cancer Competitive selection reinforces independent recognition of the scientific rationale and development potential of Marker’s multi-antigen recognizing
Marker Therapeutics (MRKR) received a $2.6M FDA grant for a Phase 1 study of MT-601, its T cell therapy for pancreatic cancer. The company has prior funding and reported promising results in a Phase 1/2 study. MT-601 targets six tumor antigens and is also being tested for lymphoma. The pancreatic cancer study is set to begin in Q1 2027.
Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphomas showed encouraging preliminary efficacy data ...
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning MRKR (Marker Therapeutics, Inc.). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Non‑dilutive funding reduces cash‑burn concerns and validates the MAR‑T platform, likely supporting modest share‑price upside.
The grant provides non‑dilutive cash and validates the program, likely supporting the stock.
Positive preliminary efficacy data for MT-601 in lymphoma patients may bolster investor confidence in Marker Therapeutics.
The announcement of the first patient treated in the off-the-shelf CAR-T cell program is positive news, indicating progress in Marker Therapeutics' pipeline.
Positive clinical trial results for MT-601 may support short-term stock stability or modest appreciation, but recent report-induced stock decline indicates market skepticism.
AlphAI scores every news story that mentions MRKR with an AI model for sentiment and relevance, and aggregates insider trades from Marker Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Marker Therapeutics, Inc. (MRKR) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant to Advance MT-601 in Pancreatic Cancer Competitive selection reinforces independent recognition of the scientific rationale and development potential of Marker’s multi-antigen recognizing
2 min readMarker Therapeutics (MRKR) received a $2.6M FDA grant for a Phase 1 study of MT-601, its T cell therapy for pancreatic cancer. The company has prior funding and reported promising results in a Phase 1/2 study. MT-601 targets six tumor antigens and is also being tested for lymphoma. The pancreatic cancer study is set to begin in Q1 2027.
2 min readOngoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphomas showed encouraging preliminary efficacy data ...
2 min readMarker Therapeutics initiated Phase 1 RAPID study to investigate Multi-Antigen Recognizing ( MAR ) T cells as an Off-the-Shelf ( OTS ) product to accelerate time to treatment ...
2 min readMT-601 shows a 66% response rate in NHL patients, with 50% achieving a complete response. No dose-limiting toxicities or serious adverse events were reported in the Phase 1 trial. See the 6X seasonal strategy set to target this fall's biggest opportunities. Details here → Marker Therapeutics, ...
2 min readHOUSTON, July 30, 2025 ( GLOBE NEWSWIRE ) -- Marker Therapeutics, Inc.
2 min readHOUSTON, July 30, 2025 ( GLOBE NEWSWIRE ) -- Marker Therapeutics, Inc. ( Nasdaq: MRKR ) , a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that ...
2 min readHOUSTON, June 17, 2025 ( GLOBE NEWSWIRE ) -- Marker Therapeutics, Inc.
2 min readHOUSTON, June 17, 2025 ( GLOBE NEWSWIRE ) -- Marker Therapeutics, Inc. ( Nasdaq: MRKR ) , a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced a ...
2 min readVirtual event with Key Opinion Leaders to discuss cell therapy landscape and shortcomings of CAR-T therapies set for May 28, 2025 Virtual event with Key Opinion Leaders to discuss cell therapy landscape and shortcomings of CAR-T therapies set for May ...
4 min read